S

Szpital Uniwersytecki W Krakowie | Oddzial Kliniczny Kardiologii Elektrokardiologii Interwencyjnej Nadcisnienia Tetniczego

Research site
(Unclaimed)
Location
Jakubowskiego 2, Krakow, Lesser Poland, Poland
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

8 of 31
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Daratumumab

The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP)...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Pomalidomide
Drug: Daratumumab

The main aim is to see how the combination of pevonedistat + venetoclax + azacitidine compares to venetoclax + azacitidine in adults recently diagnos...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Venetoclax
Drug: Pevonedistat

In this study, adults with newly-diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) will receive first-line therapy of...

Active, not recruiting
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
Drug: Cytarabine
Drug: Dexamethasone

Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the...

Enrolling
High-risk Transient Ischemic Attack
Acute Non-cardioembolic Ischemic Stroke
Drug: Placebo
Drug: Asundexian (BAY2433334)

The purpose of the study is to characterize safety and tolerability of cusatuzumab in combination with various therapies used to treat acute myeloid...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Venetoclax
Drug: Cusatuzumab

This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination wi...

Enrolling
Multiple Myeloma
Drug: Daratumumab
Drug: Iberdomide

The FANTOM II trial is intended to assess safety and performance of the Fantom Bioresorbable Coronary Scaffold in native coronary arteries.

Active, not recruiting
Coronary Artery Disease
Device: Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems